improving mds management: new targets, drug combinations, and personalized and cellular therapies
Published 2 years ago • 356 plays • Length 9:25Download video MP4
Download video MP3
Similar videos
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:14
how the ipss-m score helps personalizing treatment & combination therapies in hr-mds
-
1:31
ongoing trials in aml and hr-mds: enhance, enhance-2 and enhance-3
-
2:16
current and future treatment approaches for hr-mds
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
6:36
mds: low-risk disease treatment options
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:22
key advances in mds management
-
2:07
emerging targeted treatments for mds
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
1:04
the future of mds management
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
0:55
the role of rna modifications in mds and aml
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
0:52
the need to incorporate disease-modifying drugs in lower-risk mds
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
1:41
the role of antibody-based therapies in mds treatment
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
1:09
strategies to overcome azacitidine resistance in mds: combination strategies & mutation analysis
-
1:31
hma combination strategies in mds: blc2, cd47 & tim-3 inhibitors